Aminoalkyl-substituted flavonoids: synthesis, cholinesterase inhibition, β-amyloid aggregation, and neuroprotective study
Abstract In this manuscript, 17 aminoalkyl-substituted flavonoid derivatives were synthesized and their anticholinesterase, anti-beta-amyloid (Aβ) aggregation and neuroprotective activities were evaluated. The synthesized compounds were prepared through four-step reaction, started from the reaction between 2-hydroxyacetophenone and 4-methoxy benzaldehyde. Among the final compounds, 6j displayed the best anti-butyrylcholinesterase activity ($ IC_{50} $ = 0.335 μM). Moreover, compound 6i significantly protected PC12 neurons against $ H_{2} $$ O_{2} $-induced cell death. This compound could also inhibit acetylcholinesterase and self-induced Aβ peptide aggregation by 51.3% and 49.2%, respectively. The results indicated that compound 6i could be considered as a lead compound towards the discovery of disease-modifying drugs for Alzheimer’s disease (AD) therapy..
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2019 |
---|---|
Erschienen: |
2019 |
Enthalten in: |
Zur Gesamtaufnahme - volume:28 |
---|---|
Enthalten in: |
Medicinal chemistry research - 28(2019), 7 vom: 23. Mai, Seite 974-983 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Faraji, Laleh [VerfasserIn] |
---|
Links: |
Volltext [lizenzpflichtig] |
---|
Themen: |
---|
Anmerkungen: |
© Springer Science+Business Media, LLC, part of Springer Nature 2019 |
---|
doi: |
10.1007/s00044-019-02350-4 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
OLC2096116570 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | OLC2096116570 | ||
003 | DE-627 | ||
005 | 20230331233044.0 | ||
007 | cr uuu---uuuuu | ||
008 | 230331s2019 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s00044-019-02350-4 |2 doi | |
035 | |a (DE-627)OLC2096116570 | ||
035 | |a (DE-He213)s00044-019-02350-4-e | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | 4 | |a 540 |a 610 |q VZ |
084 | |a PHARM |q DE-84 |2 fid | ||
100 | 1 | |a Faraji, Laleh |e verfasserin |4 aut | |
245 | 1 | 0 | |a Aminoalkyl-substituted flavonoids: synthesis, cholinesterase inhibition, β-amyloid aggregation, and neuroprotective study |
264 | 1 | |c 2019 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a © Springer Science+Business Media, LLC, part of Springer Nature 2019 | ||
520 | |a Abstract In this manuscript, 17 aminoalkyl-substituted flavonoid derivatives were synthesized and their anticholinesterase, anti-beta-amyloid (Aβ) aggregation and neuroprotective activities were evaluated. The synthesized compounds were prepared through four-step reaction, started from the reaction between 2-hydroxyacetophenone and 4-methoxy benzaldehyde. Among the final compounds, 6j displayed the best anti-butyrylcholinesterase activity ($ IC_{50} $ = 0.335 μM). Moreover, compound 6i significantly protected PC12 neurons against $ H_{2} $$ O_{2} $-induced cell death. This compound could also inhibit acetylcholinesterase and self-induced Aβ peptide aggregation by 51.3% and 49.2%, respectively. The results indicated that compound 6i could be considered as a lead compound towards the discovery of disease-modifying drugs for Alzheimer’s disease (AD) therapy. | ||
650 | 4 | |a Alzheimer’s disease | |
650 | 4 | |a Flavonoid | |
650 | 4 | |a Synthetic chemistry | |
700 | 1 | |a Nadri, Hamid |4 aut | |
700 | 1 | |a Moradi, Alireza |4 aut | |
700 | 1 | |a Bukhari, Syed Nasir Abbas |4 aut | |
700 | 1 | |a Pakseresht, Bahar |4 aut | |
700 | 1 | |a Moghadam, Farshad Homayouni |4 aut | |
700 | 1 | |a Moghimi, Setareh |4 aut | |
700 | 1 | |a Abdollahi, Mohammad |4 aut | |
700 | 1 | |a Khoobi, Mehdi |4 aut | |
700 | 1 | |a Foroumadi, Alireza |0 (orcid)0000-0003-2416-5611 |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Medicinal chemistry research |d Springer US, 1991 |g 28(2019), 7 vom: 23. Mai, Seite 974-983 |h Online-Ressource |w (DE-627)490223427 |w (DE-600)2191978-1 |w (DE-576)262493225 |x 1554-8120 |7 nnns |
773 | 1 | 8 | |g volume:28 |g year:2019 |g number:7 |g day:23 |g month:05 |g pages:974-983 |
856 | 4 | 0 | |u https://dx.doi.org/10.1007/s00044-019-02350-4 |z lizenzpflichtig |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_OLC | ||
912 | |a FID-PHARM | ||
912 | |a SSG-OPC-PHA | ||
912 | |a GBV_ILN_11 | ||
912 | |a GBV_ILN_20 | ||
912 | |a GBV_ILN_22 | ||
912 | |a GBV_ILN_23 | ||
912 | |a GBV_ILN_31 | ||
912 | |a GBV_ILN_32 | ||
912 | |a GBV_ILN_39 | ||
912 | |a GBV_ILN_40 | ||
912 | |a GBV_ILN_60 | ||
912 | |a GBV_ILN_62 | ||
912 | |a GBV_ILN_63 | ||
912 | |a GBV_ILN_65 | ||
912 | |a GBV_ILN_69 | ||
912 | |a GBV_ILN_70 | ||
912 | |a GBV_ILN_73 | ||
912 | |a GBV_ILN_74 | ||
912 | |a GBV_ILN_90 | ||
912 | |a GBV_ILN_95 | ||
912 | |a GBV_ILN_100 | ||
912 | |a GBV_ILN_101 | ||
912 | |a GBV_ILN_105 | ||
912 | |a GBV_ILN_110 | ||
912 | |a GBV_ILN_120 | ||
912 | |a GBV_ILN_138 | ||
912 | |a GBV_ILN_150 | ||
912 | |a GBV_ILN_151 | ||
912 | |a GBV_ILN_152 | ||
912 | |a GBV_ILN_161 | ||
912 | |a GBV_ILN_170 | ||
912 | |a GBV_ILN_187 | ||
912 | |a GBV_ILN_213 | ||
912 | |a GBV_ILN_230 | ||
912 | |a GBV_ILN_285 | ||
912 | |a GBV_ILN_293 | ||
912 | |a GBV_ILN_370 | ||
912 | |a GBV_ILN_602 | ||
912 | |a GBV_ILN_636 | ||
912 | |a GBV_ILN_702 | ||
912 | |a GBV_ILN_2001 | ||
912 | |a GBV_ILN_2003 | ||
912 | |a GBV_ILN_2004 | ||
912 | |a GBV_ILN_2005 | ||
912 | |a GBV_ILN_2006 | ||
912 | |a GBV_ILN_2007 | ||
912 | |a GBV_ILN_2008 | ||
912 | |a GBV_ILN_2009 | ||
912 | |a GBV_ILN_2010 | ||
912 | |a GBV_ILN_2011 | ||
912 | |a GBV_ILN_2014 | ||
912 | |a GBV_ILN_2015 | ||
912 | |a GBV_ILN_2020 | ||
912 | |a GBV_ILN_2021 | ||
912 | |a GBV_ILN_2025 | ||
912 | |a GBV_ILN_2026 | ||
912 | |a GBV_ILN_2027 | ||
912 | |a GBV_ILN_2031 | ||
912 | |a GBV_ILN_2034 | ||
912 | |a GBV_ILN_2037 | ||
912 | |a GBV_ILN_2038 | ||
912 | |a GBV_ILN_2039 | ||
912 | |a GBV_ILN_2044 | ||
912 | |a GBV_ILN_2048 | ||
912 | |a GBV_ILN_2049 | ||
912 | |a GBV_ILN_2055 | ||
912 | |a GBV_ILN_2057 | ||
912 | |a GBV_ILN_2059 | ||
912 | |a GBV_ILN_2061 | ||
912 | |a GBV_ILN_2064 | ||
912 | |a GBV_ILN_2065 | ||
912 | |a GBV_ILN_2068 | ||
912 | |a GBV_ILN_2070 | ||
912 | |a GBV_ILN_2086 | ||
912 | |a GBV_ILN_2088 | ||
912 | |a GBV_ILN_2093 | ||
912 | |a GBV_ILN_2106 | ||
912 | |a GBV_ILN_2107 | ||
912 | |a GBV_ILN_2108 | ||
912 | |a GBV_ILN_2110 | ||
912 | |a GBV_ILN_2111 | ||
912 | |a GBV_ILN_2112 | ||
912 | |a GBV_ILN_2113 | ||
912 | |a GBV_ILN_2116 | ||
912 | |a GBV_ILN_2118 | ||
912 | |a GBV_ILN_2119 | ||
912 | |a GBV_ILN_2122 | ||
912 | |a GBV_ILN_2129 | ||
912 | |a GBV_ILN_2131 | ||
912 | |a GBV_ILN_2143 | ||
912 | |a GBV_ILN_2144 | ||
912 | |a GBV_ILN_2147 | ||
912 | |a GBV_ILN_2148 | ||
912 | |a GBV_ILN_2152 | ||
912 | |a GBV_ILN_2153 | ||
912 | |a GBV_ILN_2188 | ||
912 | |a GBV_ILN_2190 | ||
912 | |a GBV_ILN_2232 | ||
912 | |a GBV_ILN_2336 | ||
912 | |a GBV_ILN_2446 | ||
912 | |a GBV_ILN_2470 | ||
912 | |a GBV_ILN_2474 | ||
912 | |a GBV_ILN_2507 | ||
912 | |a GBV_ILN_2522 | ||
912 | |a GBV_ILN_2548 | ||
912 | |a GBV_ILN_4035 | ||
912 | |a GBV_ILN_4037 | ||
912 | |a GBV_ILN_4046 | ||
912 | |a GBV_ILN_4112 | ||
912 | |a GBV_ILN_4125 | ||
912 | |a GBV_ILN_4242 | ||
912 | |a GBV_ILN_4246 | ||
912 | |a GBV_ILN_4249 | ||
912 | |a GBV_ILN_4251 | ||
912 | |a GBV_ILN_4305 | ||
912 | |a GBV_ILN_4306 | ||
912 | |a GBV_ILN_4307 | ||
912 | |a GBV_ILN_4313 | ||
912 | |a GBV_ILN_4322 | ||
912 | |a GBV_ILN_4323 | ||
912 | |a GBV_ILN_4324 | ||
912 | |a GBV_ILN_4325 | ||
912 | |a GBV_ILN_4326 | ||
912 | |a GBV_ILN_4333 | ||
912 | |a GBV_ILN_4334 | ||
912 | |a GBV_ILN_4335 | ||
912 | |a GBV_ILN_4336 | ||
912 | |a GBV_ILN_4338 | ||
912 | |a GBV_ILN_4393 | ||
912 | |a GBV_ILN_4700 | ||
951 | |a AR | ||
952 | |d 28 |j 2019 |e 7 |b 23 |c 05 |h 974-983 |